Prostate Cancer News and Research

Latest Prostate Cancer News and Research

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it is initiating a multicenter Phase 2b clinical trial with its oncology drug candidate tamibarotene in combination with chemotherapeutical agents for the treatment of patients with advanced non-small-cell lung cancer (NSCLC).

2 Dec 2010

American-style diet plays a vital role in prostate cancer, researchers say

Elevated fat and cholesterol levels found in a typical American-style diet plays an important role in the growth and spread of prostate cancer, say researchers at Thomas Jefferson University's Kimmel Cancer Center.

2 Dec 2010

Finger length may predict prostate cancer

In a new study published in the British Journal of Cancer, researchers have revealed a connection between finger length and prostate cancer. It says that men whose ring fingers are longer than their index fingers are more likely to develop prostate cancer.

1 Dec 2010

Debiopharm recognised with European Biopharmaceuticals company of the year award

The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm).

1 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Men with long index fingers at lower risk of prostate cancer

Men who have long index fingers are at lower risk of prostate cancer, a new study published today in the British Journal of Cancer has found.

1 Dec 2010

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

GenSpera, Inc. announced its intention to expand its Phase I safety trial to study G-202 in relapsed, refractory cancer patients to the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, TX. The expansion is dependent upon a successful review of the clinical protocol by the Health Science Center Institutional Review Board (IRB). The company anticipates admitting the first patient at this site in the first quarter of 2011.

1 Dec 2010

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

30 Nov 2010

New tool to trace metabolism of carotenoids in human body

The University of Illinois scientists who linked eating tomatoes with a reduced risk of prostate cancer have developed a tool that will help them trace the metabolism of tomato carotenoids in the human body. And they've secured funding from the National Institutes of Health to do it.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010

LCA calls for public discussion on guidance for lung cancer screening

Today, Lung Cancer Alliance (LCA) President & CEO Laurie Fenton-Ambrose said the recent breakthrough on CT screening for lung cancer is an extraordinary development in the battle against lung cancer and reiterated her call for an open and balanced public discussion on guidance for those at high risk who may be considering a scan.

25 Nov 2010

Bref Rhone-Alpes honors EDAP with Best 2010 Product Innovation award for Sonolith i-move lithotripter

EDAP TMS SA, the global leader in therapeutic ultrasound, reported today that its new lithotripter Sonolith i-move received the Best 2010 Product Innovation award by the French economic journal Bref Rhone-Alpes. The award was presented on November 22, 2010 at a gathering of all major local economic and financial partners.

24 Nov 2010

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office has granted patent #7,829,668, entitled Compositions and methods for modifying toxic effects of proteinaceous compounds.

22 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer's clinical stage and a patient's risk of cancer recurrence after having his prostate removed.

22 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

American-style diet plays a vital role in prostate cancer, researchers say

Finger length may predict prostate cancer

Debiopharm recognised with European Biopharmaceuticals company of the year award

Active surveillance improves quality of life in low-risk prostate cancer patients

Men with long index fingers at lower risk of prostate cancer

GenSpera expands G-202 Phase I safety trial to CTRC at University of Texas Health Science Center

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

New tool to trace metabolism of carotenoids in human body

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

LCA calls for public discussion on guidance for lung cancer screening

Bref Rhone-Alpes honors EDAP with Best 2010 Product Innovation award for Sonolith i-move lithotripter

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

IsoRay to sell $2.25 million in common stock

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in